Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Clinical Genitourinary Cancer
|
March 21, 2026
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer
Brendan L Raizenne, Vadim S Koshkin, Alec Zhu, et al.
Urologic Oncology
|
November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers
Daniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Carissa E Chu, Martin Sjöström, Emily A Egusa, et al.
Cancer Immunology Research
|
January 26, 2024
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Hewitt Chang, Jaqueline Marquez, Brandon K Chen, et al.
European Urology Oncology
|
June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab
Kevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Cancer Letters
|
June 26, 2016
An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer
Gayatri Premasekharan, Elizabeth Gilbert, Ross A Okimoto, et al.
Cell
|
June 5, 2020
Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
David Y Oh, Serena S Kwek, Siddharth S Raju, et al.
JAMA Oncology
|
August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
Thomas Powles, Peter H O'Donnell, Christophe Massard, et al.
European Urology Oncology
|
February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells
Jonathan Chou, Kai Trepka, Martin Sjöström, et al.
Clinical Genitourinary Cancer
|
June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer
Terence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Clinical Genitourinary Cancer
|
March 21, 2026
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer
Brendan L Raizenne, Vadim S Koshkin, Alec Zhu, et al.
Urologic Oncology
|
November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers
Daniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Carissa E Chu, Martin Sjöström, Emily A Egusa, et al.
Cancer Immunology Research
|
January 26, 2024
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Hewitt Chang, Jaqueline Marquez, Brandon K Chen, et al.
European Urology Oncology
|
June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab
Kevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Cancer Letters
|
June 26, 2016
An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer
Gayatri Premasekharan, Elizabeth Gilbert, Ross A Okimoto, et al.
Cell
|
June 5, 2020
Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
David Y Oh, Serena S Kwek, Siddharth S Raju, et al.
JAMA Oncology
|
August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study
Thomas Powles, Peter H O'Donnell, Christophe Massard, et al.
European Urology Oncology
|
February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells
Jonathan Chou, Kai Trepka, Martin Sjöström, et al.
Clinical Genitourinary Cancer
|
June 29, 2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer
Terence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, et al.
Page
of 5